Results 1 to 10 of about 229,463 (145)

Parameter estimation and treatment optimization in a stochastic model for immunotherapy of cancer [PDF]

open access: yes, 2020
Adoptive Cell Transfer therapy of cancer is currently in full development and mathematical modeling is playing a critical role in this area. We study a stochastic model developed by Baar et al.
Coquille, Loren   +2 more
core   +2 more sources

New roles for Fc receptors in neurodegeneration-the impact on immunotherapy for Alzheimer's disease [PDF]

open access: yes, 2014
There are an estimated 18 million Alzheimer's disease (AD) sufferers worldwide and with no disease modifying treatment currently available, development of new therapies represents an enormous unmet clinical need.
Fuller, James P.   +2 more
core   +8 more sources

A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis [PDF]

open access: yes, 2013
© Queen’s Printer and Controller of HMSO 2013Severe allergic rhinitis uncontrolled by conventional medication can substantially affect quality of life. Immunotherapy involves administering increasing doses of a specific allergen, with the aim of reducing
Barton, P   +7 more
core   +1 more source

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. [PDF]

open access: yes, 2016
Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being ...
Bander, Neil H   +17 more
core   +1 more source

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. [PDF]

open access: yes, 2017
Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse ...
Abdallah, K.   +80 more
core   +2 more sources

The ambitious role of anti angiogenesis molecules: Turning a cold tumor into a hot one [PDF]

open access: yes, 2018
In renal cancer emerging treatment options are becoming available and there is a strong need to combine therapies to reformulate and adjourn clinical practice.
Botticelli, A.   +4 more
core   +1 more source

Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma [PDF]

open access: yes, 2019
Background: Sublingual allergen immunotherapy (SLIT) has been demonstrated to be both clinically efficacious and safe. However, in line with the current regulatory guidance from the European Medicines Agency, allergen immunotherapy (AIT) products must ...
Bachert, Claus   +10 more
core   +2 more sources

The future outlook on allergen immunotherapy in children: 2018 and beyond. [PDF]

open access: yes, 2018
Allergen immunotherapy (AIT) is the only currently available immune-modifying and aetiological treatment for patients suffering from IgE-mediated diseases.
Arasi S, Corsello G, Pajno GB, Villani A
core   +2 more sources

Hepatocellular carcinoma and multidrug resistance: Past, present and new challenges for therapy improvement [PDF]

open access: yes, 2015
Hepatocellular carcinoma (HCC) is the most common malignancy of the liver and the third cause of cancer death worldwide. Chronic hepatitis due to HBV and HCV infection are two major risk factors for HCC worldwide.
Cuestas, María Luján   +2 more
core   +1 more source

Immunotherapy of lung cancer: An update [PDF]

open access: yes, 2006
In Germany lung cancer is the leading cause of cancer-associated death in men. Surgery, chemotherapy and radiation may enhance survival of patients suffering from lung cancer but the enhancement is typically transient and mostly absent with advanced ...
Aman MJ   +36 more
core   +1 more source

Home - About - Disclaimer - Privacy